Medical devices versus medicines: two different regulatory worlds

People often use the term "medical products" loosely, but health regulators draw a sharp legal line between medicines and medical devices. A medicine, or pharmaceutical, achieves its primary purpose through pharmacological, immunological, or metabolic action inside the body. A medical device, by contrast, achieves its primary purpose through physical or mechanical means—such as a scalpel cutting tissue, a pump infusing fluid, or a pacemaker delivering an electrical pulse. Because their modes of action differ so fundamentally, regulators around the world maintain entirely separate legal frameworks, approval processes, and post-market surveillance systems for each category.

How medical devices are classified by risk

Instead of being grouped by their chemical active ingredient or therapeutic effect, medical devices are classified according to the level of risk they pose to the patient. The International Medical Device Regulators Forum (IMDRF), whose guidelines are adopted by many national authorities, outlines a risk-based classification system. In South Africa and many other jurisdictions, devices are generally grouped into Classes A, B, C, and D. Class A represents low-risk items, such as manual wheelchairs, surgical retractors, or adhesive bandages. Class B covers low-to-moderate-risk devices like contact lenses and non-invasive suction equipment.

Class C encompasses moderate-to-high-risk devices, including orthopaedic implants, diagnostic ultrasound machines, and lung ventilators. Class D represents high-risk devices that sustain or support life, such as cardiac pacemakers, artificial heart valves, and implantable neurostimulators. The classification depends on factors like the duration of contact with the body, the degree of invasiveness, and whether the device delivers energy or medicine to the patient. A low-risk Class A device generally requires minimal regulatory oversight to enter the market, whereas a Class D device requires rigorous scientific evaluation before it can be sold.

Why the approval route differs

The approval process for a medicine typically relies on large-scale, phased clinical trials designed to prove both efficacy and safety. Because a medicine interacts chemically with human biology, regulators must thoroughly understand how it is absorbed, distributed, metabolised, and excreted, alongside its side-effect profile in diverse populations. The evaluation focuses heavily on the pharmaceutical active ingredient.

Medical devices, however, are generally evaluated through an engineering and performance lens. Regulators focus on design controls, biocompatibility (whether the device's materials cause harm to human tissues), and adherence to quality management standards like ISO 13485. While clinical data is still required for higher-risk devices, it is often gathered through smaller, targeted clinical evaluations rather than the multi-phase trials used for drugs. Furthermore, devices undergo iterative design improvements over their lifecycle. A manufacturer might slightly alter the materials in a surgical instrument or update the software in an MRI machine. Because of this, regulators often require periodic re-certification or quality audits rather than a single, lifelong approval. Post-market surveillance for devices also differs, focusing on adverse incidents, mechanical failures, and field safety corrective actions rather than the adverse drug reaction reports central to medicine pharmacovigilance.

Combination products and borderline cases

Not every product fits neatly into a single regulatory category. Combination products contain both a medical device and a medicine, such as a pre-filled insulin syringe or a drug-eluting stent. In these cases, regulators must determine which component provides the primary mode of action. If a device's primary function is simply to deliver a medicine, like a metered-dose inhaler, the medicine is usually regulated under the pharmaceutical framework, while the device component is evaluated for mechanical safety and compatibility.

If the device and medicine act together synergistically, the product may require review by both the drug and device divisions of the regulatory authority. In South Africa, this regulatory distinction also affects economics. Medicines are generally subject to the Single Exit Price (SEP) framework, a regulated pricing structure ensuring transparency, whereas medical devices are typically subject to different pricing and reimbursement mechanisms. Determining whether a product is legally a device or a medicine dictates which regulatory pathway and pricing rules apply.

SAHPRA and device regulation in South Africa

In South Africa, the South African Health Products Regulatory Authority (SAHPRA) serves as the statutory body overseeing both medicines and medical devices. While the regulation of medicines has a long history in the country, comprehensive medical device regulation was formally established more recently as SAHPRA took over from the legacy Medicines Control Council. SAHPRA's medical devices unit requires manufacturers and distributors to obtain establishment licences and to register higher-risk devices before they can be legally sold.

Consumers and healthcare professionals can use HealthSA to search medicine registration details and Single Exit Price information, but medical device registrations are maintained in separate SAHPRA databases. The global regulatory landscape for devices continues to evolve, driven by the need to ensure that everything from surgical gloves to robotic surgery systems is appropriately vetted for public safety. Understanding that these two regulatory worlds operate side by side helps clarify why a new inhaler might face a different approval timeline than a new blood pressure monitor, even though both are essential to patient care.